Bioxcel Therapeutics Inc (BTAI)

May 23, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

May 23, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria

May 23, 2026

May 23, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India

May 23, 2026

May 23, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

May 22, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India

May 22, 2026

May 22, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK

May 22, 2026

May 22, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com

May 22, 2026

May 22, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com

May 22, 2026

May 22, 2026

BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan

May 22, 2026

May 22, 2026

BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan

May 22, 2026

May 22, 2026

BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan

May 22, 2026

May 22, 2026

BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan

May 22, 2026

May 22, 2026

BioXcel Shareholder Notice - TMX Newsfile

May 22, 2026

May 22, 2026

BTAI Should I Buy - Intellectia AI

May 22, 2026

May 20, 2026

BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan

May 20, 2026

May 20, 2026

BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan

May 20, 2026

May 20, 2026

BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan

May 20, 2026

May 20, 2026

[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan

May 20, 2026

May 18, 2026

Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus

May 18, 2026

May 18, 2026

BioXcel Therapeutics, Inc. (BTAI) reports Q1 loss, lags revenue estimates - MSN

May 18, 2026

May 17, 2026

Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026 Results? - GuruFocus

May 17, 2026

May 15, 2026

BioXcel Therapeutics (BTAI) Reports First Quarter Revenue and Re - GuruFocus

May 15, 2026

May 15, 2026

BioXcel Therapeutics 1Q Loss $12.7M >BTAI - Moomoo

May 15, 2026

May 15, 2026

Press Release: BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo

May 15, 2026

May 15, 2026

BioXcel Therapeutics Reports Q1 2026 Results, FDA Accepts IGALMI sNDA for At-Home Use, and Explores Strategic Options - Minichart

May 15, 2026

May 15, 2026

Armistice Capital reports 7.05% stake in BioXcel (NASDAQ: BTAI) - Stock Titan

May 15, 2026

May 15, 2026

BioXcel weighs sale, other strategic options as New Haven biotech continues losses - Hartford Business Journal

May 15, 2026

May 15, 2026

BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan

May 15, 2026

May 15, 2026

BioXcel Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 15, 2026

May 15, 2026

BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

May 15, 2026

May 15, 2026

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 15, 2026

May 15, 2026

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times

May 15, 2026

May 15, 2026

BioXcel Therapeut reports Q1 2026 net loss $12.7M, revenue $0.2M; FDA sets IGALMI at-home PDUFA Nov 14, 2026 - TradingView

May 15, 2026

May 15, 2026

BioXcel Therapeutics 1Q 2026: Revenue $206K, Net income ($12.69M), EPS ($0.54) — 10-Q Summary - TradingView

May 15, 2026

May 15, 2026

BioXcel Therapeutics (NASDAQ: BTAI) posts Q1 2026 loss, limited cash and going concern risk - Stock Titan

May 15, 2026

May 15, 2026

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

May 15, 2026

BioXcel Therapeutics (BTAI) posts Q1 2026 loss amid going concern risk - Stock Titan

May 15, 2026

May 15, 2026

BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date - Stock Titan

May 15, 2026

May 12, 2026

Number of shareholders of BioXcel Therapeutics, Inc. – SWB:BX20 - TradingView

May 12, 2026

May 11, 2026

AI For Pharma And Biotech Market Is Going to Boom | BioXcel Therapeutics, BenevolentAI, NVIDIA Corporation - openPR.com

May 11, 2026

May 08, 2026

BioXcel Therapeutics, Inc. (BTAI) Latest Stock News & Headlines - Yahoo Finance

May 08, 2026

May 07, 2026

BioXcel Therapeutics (BTAI) CEO exercises 18,000 RSUs, updates share holdings - Stock Titan

May 07, 2026

May 07, 2026

BioXcel Therapeutics (BTAI) CFO converts 9,000 RSUs, now holds 15,645 shares - Stock Titan

May 07, 2026

May 07, 2026

BioXcel (NASDAQ: BTAI) CSO converts 9,000 RSUs to stock - Stock Titan

May 07, 2026

May 07, 2026

Javier Rodriguez of BioXcel (NASDAQ: BTAI) converts 9,000 RSUs to shares - Stock Titan

May 07, 2026

May 06, 2026

BioXcel Deadline Alert - TMX Newsfile

May 06, 2026

May 06, 2026

BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN

May 06, 2026

May 04, 2026

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

May 04, 2026

Apr 25, 2026

BioXcel Shareholder Action Reminder - TMX Newsfile

Apr 25, 2026